Gilead Sciences (NASDAQ:GILD) Price Target Raised to $96.00 at UBS Group

22 Nov 2024, 18:40 by Kim Johansen · The Markets Daily

Gilead Sciences (NASDAQ:GILD – Free Report) had its price target upped by UBS Group from $70.00 to $96.00 in a report issued on Thursday,Benzinga reports. UBS Group currently has a neutral rating on the biopharmaceutical company’s stock.

Other research analysts also recently issued research reports about the stock. Citigroup began coverage on shares of Gilead Sciences in a research report on Thursday, November 14th. They set a “buy” rating and a $125.00 target price on the stock. Evercore ISI raised shares of Gilead Sciences to a “strong-buy” rating in a research report on Friday, August 9th. Daiwa America raised shares of Gilead Sciences to a “hold” rating in a research report on Monday. Leerink Partnrs raised shares of Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 21st. Finally, BMO Capital Markets lifted their price objective on shares of Gilead Sciences from $94.00 to $102.00 and gave the stock an “outperform” rating in a research report on Thursday, November 7th. Twelve analysts have rated the stock with a hold rating, eleven have assigned a buy rating and four have issued a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $95.41.

Read Our Latest Report on Gilead Sciences

Gilead Sciences Trading Up 1.4 %

GILD stock opened at $89.84 on Thursday. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10. The company has a market capitalization of $111.96 billion, a PE ratio of 998.22, a P/E/G ratio of 2.72 and a beta of 0.17. The firm’s 50-day moving average is $87.28 and its 200 day moving average is $76.61. Gilead Sciences has a 12 month low of $62.07 and a 12 month high of $98.90.

Gilead Sciences (NASDAQ:GILD – Get Free Report) last posted its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, beating analysts’ consensus estimates of $1.58 by $0.44. The business had revenue of $7.55 billion for the quarter, compared to the consensus estimate of $7.01 billion. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The company’s revenue for the quarter was up 7.0% on a year-over-year basis. During the same quarter last year, the firm posted $2.29 EPS. On average, research analysts anticipate that Gilead Sciences will post 4.38 EPS for the current year.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 30th. Shareholders of record on Friday, December 13th will be paid a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a yield of 3.43%. The ex-dividend date is Friday, December 13th. Gilead Sciences’s payout ratio is 3,422.22%.

Insider Buying and Selling at Gilead Sciences

In other news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $83.83, for a total transaction of $167,660.00. Following the completion of the transaction, the insider now directly owns 100,189 shares of the company’s stock, valued at $8,398,843.87. The trade was a 1.96 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Johanna Mercier sold 29,357 shares of Gilead Sciences stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the transaction, the insider now directly owns 78,127 shares of the company’s stock, valued at approximately $6,545,480.06. This trade represents a 27.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 56,947 shares of company stock worth $4,968,674. Company insiders own 0.16% of the company’s stock.

Hedge Funds Weigh In On Gilead Sciences

Institutional investors have recently made changes to their positions in the company. SkyView Investment Advisors LLC increased its holdings in Gilead Sciences by 5.4% in the 3rd quarter. SkyView Investment Advisors LLC now owns 8,482 shares of the biopharmaceutical company’s stock worth $711,000 after acquiring an additional 435 shares in the last quarter. Tri Ri Asset Management Corp purchased a new stake in Gilead Sciences in the 3rd quarter worth $3,163,000. Westside Investment Management Inc. grew its holdings in shares of Gilead Sciences by 3.5% during the third quarter. Westside Investment Management Inc. now owns 27,443 shares of the biopharmaceutical company’s stock worth $2,249,000 after buying an additional 917 shares in the last quarter. Rehmann Capital Advisory Group grew its holdings in shares of Gilead Sciences by 3.6% during the third quarter. Rehmann Capital Advisory Group now owns 9,626 shares of the biopharmaceutical company’s stock worth $807,000 after buying an additional 333 shares in the last quarter. Finally, TD Private Client Wealth LLC grew its holdings in shares of Gilead Sciences by 10.6% during the third quarter. TD Private Client Wealth LLC now owns 57,509 shares of the biopharmaceutical company’s stock worth $4,822,000 after buying an additional 5,497 shares in the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences Company Profile

(Get Free Report)